Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

A Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
Immunomedics, Inc.
ClinicalTrials.gov Identifier:
NCT01510561
First received: January 5, 2012
Last updated: March 13, 2013
Last verified: March 2013

January 5, 2012
March 13, 2013
March 2012
June 2014   (final data collection date for primary outcome measure)
Safety (change in hematology and chemistry laboratory values from baseline) [ Time Frame: 1 year ] [ Designated as safety issue: Yes ]
Acute safety will be assessed weekly for the 1st 12 weeks, and then for up to 1 year after completion of study drug treatment. Safety will be assessed by comparing baseline hematology and chemistry laboratory values with the values obtained weekly after treatment. Safety will also be assessed by the adverse events that are reported.
Same as current
Complete list of historical versions of study NCT01510561 on ClinicalTrials.gov Archive Site
  • Dosage determination [ Time Frame: 2 years ] [ Designated as safety issue: Yes ]
    This study is also being done to determine an acceptable 90Y-hPAM4 dose in this patient population. It is anticipated that enrollment will occur over 2 years.
  • Efficacy [ Time Frame: 1 year ] [ Designated as safety issue: No ]
    Efficacy will be assessed for at least 1 year after treatment with study drug. CT scans will be used to determine treatment response.
Same as current
Not Provided
Not Provided
 
A Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.
A Ph Ib Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.

90Y-hPAM4 is administered weekly for 3 weeks combined with 4 weekly doses of gemcitabine to assess. This is a dose escalation study of 90Y-hPAM4 to assess which dose is safe and effective as 3rd line treatment for patients with metastatic pancreatic cancer. Patients are then followed weekly for 12 weeks and afterwards for up to 1 year.

Not Provided
Interventional
Phase 1
Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
  • Metastatic Pancreatic Adenocarcinoma
  • Pancreatic Cancer
  • Metastatic Pancreatic Cancer
  • Drug: 90Y-hPAM4
    90Y-hPAM4 will be administered weekly for 3 weeks in conjunction with gemcitabine which will be administered weekly x 4.
    Other Name: Clivatuzumab Tetraxetan
  • Drug: 90Y-hPAM4
    Other Name: clivatuzumab tetraxetan
  • Drug: 90Y-hPAM4 + gemcitabine
    Other Names:
    • gemzar
    • clivatuzumab tetraxetan
  • Experimental: 90Y-hPAM4
    90Y-hPAM4 is administered weekly for 3 weeks
    Interventions:
    • Drug: 90Y-hPAM4
    • Drug: 90Y-hPAM4
  • Experimental: 90Y-hPAM4 + gemcitabine
    90Y-hPAM4 is administered weekly for 3 weeks, while gemcitabine is administered weekly for 4 weeks.
    Interventions:
    • Drug: 90Y-hPAM4
    • Drug: 90Y-hPAM4
    • Drug: 90Y-hPAM4 + gemcitabine
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
50
March 2015
June 2014   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Male or female patients, ≥ 18 years of age, who are able to understand and give written informed consent
  • Histologically or cytologically confirmed pancreatic adenocarcinoma
  • Stage IV (metastatic) disease, including patients who underwent surgery but had incomplete resections
  • Previously treated and received two prior treatment regimens for advanced disease
  • Karnofsky performance status ≥ 60 % (Appendix A)
  • Expected survival ≥ 3 months
  • At least 4 weeks beyond major surgery, 2 weeks beyond chemotherapy, radiotherapy, other experimental treatments
  • At least 2 weeks beyond corticosteroids, except low doses (i.e., 20 mg/day of prednisone or equivalent) to treat nausea or other illness such as rheumatoid arthritis
  • Adequate hematology without ongoing transfusional support (hemoglobin > 9 g/dL, ANC > 1,500 per mm3, platelets > 100,000 per mm3)
  • Adequate renal and hepatic function (creatinine and bilirubin ≤ 1.5 X IULN, AST and ALT ≤ 2.0 X IULN [5.0 X IULN if due to liver metastases])
  • Otherwise, all toxicity at study entry ≤ Grade 1 by NCI CTC v3.0 or recovered to baseline or discussed with and agreed to with Immunomedics' Medical Monitor.

Exclusion Criteria:

  • Women who are pregnant or lactating
  • Women of childbearing potential and fertile men unwilling to use effective contraception during study until conclusion of 12-week post-treatment evaluation period
  • Known metastatic disease to the central nervous system
  • Presence of bulky disease (defined as any single mass > 10 cm in its greatest dimension)
  • Patients with > Grade 2 nausea or vomiting and/or signs of intestinal obstruction
  • Prior radiation dose > 3,000 cGy to the liver, > 2,000 cGy to lungs and kidneys or prior external beam irradiation to a field that includes more than 30% of the red marrow
  • Patients with non-melanoma skin cancer or carcinoma in situ of the cervix are not excluded, but patients with other prior malignancies must have had at least a 3-year disease free interval
  • Patients known to be HIV positive, hepatitis B positive, or hepatitis C positive
  • Known history of active coronary artery disease, unstable angina, myocardial infarction, or congestive heart failure present within 6 months, or cardiac arrhythmia (other than stable atrial fibrillation) requiring anti-arrhythmia therapy
  • Known history of active COPD, or other moderate-to-severe respiratory illness present within 6 months
  • Known autoimmune disease or presence of autoimmune phenomena (except rheumatoid arthritis requiring only low dose maintenance corticosteroids)
  • Infection requiring intravenous antibiotic use within 1 week
  • Other concurrent medical or psychiatric conditions that, in the Investigator's opinion, may be likely to confound study interpretation or prevent completion of study procedures and follow-up examinations
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT01510561
IM-T-hPAM4-03
No
Immunomedics, Inc.
Immunomedics, Inc.
Not Provided
Study Chair: William A Wegener, MD, PhD Immunomedics, Inc.
Immunomedics, Inc.
March 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP